News and Trends 14 Sep 2015
64 million infected: A brief overview of ReViral and its RSV vaccine competition
Respiratory Syncytial Virus (RSV) affects millions annually, therefore attracting many large biotechs to research a vaccine. ReViral (London, UK) has secured €18.5M series A investment into its pre-clinical pipeline. VC investors Edmond de Rothschild, OrbiMed and Brace Pharma Capital back this award winning antiviral program, despite an array of competitors. ReViral have got the go […]